Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. - Wikidata - awgldk - TriplyDB

Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

http://www.wikidata.org/entity/Q38739710

about

Mast Cell Clonal Disorders: Classification, Diagnosis and Management Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients.Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis.Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis.Mastocytosis - pathogenesis, clinical manifestation and treatment.Mastozytose - Pathogenese, Klinik und Therapie.Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series.[Severe therapy refractive osteoporosis : A rare differential diagnosis].[Mastocytosis : Clinical aspects, diagnostics, therapy].

P2860

Q28070386-A134C716-B305-4AC8-A9C2-4DF55CB1570E Q33431360-B51B5ADE-9802-44E5-B183-D7B2FB8CC045 Q39289490-30874B98-65DE-4002-9215-B921EF8CA12A Q47158405-96DA602B-AA1B-4C10-8D52-479EFDD6FD62 Q50122626-FD4AE444-1BB7-4832-8107-70366B2A9C2E Q50122660-708FCAE6-3AD2-423F-A32C-EA66A7C5E6BD Q51272075-BD8D5E78-1075-49A3-9877-E9EE33D4810D Q52852170-83FE5F54-AD4C-4F11-A358-68C94666E8CE Q53756889-9940F892-E4D4-430E-B660-E840581172F5

P2860

Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

http://www.wikidata.org/entity/Q38739710

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

@en

type

label

Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

@en

prefLabel

Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

@en

P1433

Q38739710-4C622D4A-DA0A-454A-AC5E-3064FB60F01E

P1476

Q38739710-4759C107-1EC7-4D60-B339-98BD1CF0E1B4

P2093

Q38739710-3039D4C9-DBB7-46F9-84F7-87F8EC31EBF5

Q38739710-AF87C3F0-E249-49AC-925B-6916DE26CE7D

Q38739710-BD09A54F-C36D-4716-9275-63D45B828738

Q38739710-C509EB75-B3F1-44C7-951B-AD2BC2AECE26

Q38739710-EC6CCAA1-DFC5-4E37-AF73-1FECBAE203E2

Q38739710-F01A7AFF-A7E2-4F3A-B2C3-C639DC394101

P2860

Q38739710-00CA5E1E-9295-457A-977E-659A787FA8D4

Q38739710-02299291-1C6D-43E3-910E-1D2BAD9948FB

Q38739710-06E25A12-F2F0-4B40-A922-8E20D7966E7E

Q38739710-07975826-C7B2-4D6B-898C-DB029B848034

Q38739710-11612C13-CF51-4583-823B-FCE503E2E153

Q38739710-16F07143-660E-4092-AA6C-9D2CD1B978C7

Q38739710-19493252-47D4-4644-BC6A-11AA25C0C59B

Q38739710-25993E88-6C70-4D33-B607-C7A7049C3615

Q38739710-2AF7A2B7-CA47-4BEB-BDF4-A11C53CF87D7

Q38739710-2DAD2040-5E4E-4437-AAFA-1310250A2CBF

P2888

Q38739710-864C9A0A-95E5-49BF-9ACD-05A13C636A1D

P304

Q38739710-71177ACE-5ACF-4885-A78A-452908DEAA3C

P31

Q38739710-1B9112B7-03D9-4B97-9C25-25CA8C042D2E

P356

Q38739710-913EAC46-FAE9-4F70-BF93-D372E4C43807

P407

Q38739710-DAD5FCE5-3C11-4D4A-A49B-A36C444E2AF2

P433

Q38739710-A7343041-2B7A-4062-8237-E5AB2D7391F8

P478

Q38739710-0F1A4258-F486-42A9-8864-E37E324E230C

P50

Q38739710-60B40D99-D849-415A-9FD6-1398F3EFA81B

Q38739710-914E90B0-6FE6-4600-9C8E-BD79B6492E5B

Q38739710-BA33AD91-E5A6-4A7A-834C-3EF0BDD6C5C0

Q38739710-E1229D9C-FB7C-4396-8119-114B57CA1FE2

Q38739710-F0FC598E-80BF-4FBF-84AC-C70C42DCC608

P577

Q38739710-D9AD77E7-8FB1-4AC7-AE35-6D2D3F1F38C9

P6179

Q38739710-E64F43EE-BF62-4749-B095-0264A98D3DBA

P698

Q38739710-11FE4AF5-E9E8-4C56-B989-DA6CB38CF826

P356

S00198-016-3539-1

P1433

Osteoporosis International

P1476

Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis

@en

P2093

G Orsolini

http://www.w3.org/2001/XMLSchema#string

G Tripi

http://www.w3.org/2001/XMLSchema#string

O Viapiana

http://www.w3.org/2001/XMLSchema#string

P Bonadonna

http://www.w3.org/2001/XMLSchema#string

R Zanotti

http://www.w3.org/2001/XMLSchema#string

S Adami

http://www.w3.org/2001/XMLSchema#string

P2860

Case-control cohort study of patients' perceptions of disability in mastocytosis

Current options in the treatment of mast cell mediator-related symptoms in mastocytosis.

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

Mastocytosis: current treatment concepts.

Gastrointestinal manifestations of systemic mastocytosis

Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.

Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss

The role of mast cells in parathyroid bone disease.

Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.

The role of mast cells in osteoporosis.

P2888

s00198-016-3539-1

P304

2411-2421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-016-3539-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Vidya Kunnathully

Maurizio Rossini

P577

2016-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1020746212

http://www.w3.org/2001/XMLSchema#string

P698

26892042

http://www.w3.org/2001/XMLSchema#string